Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ikena Oncology, Inc. - Common Stock (NQ:IKNA)

1.290 -0.130 (-9.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ikena Oncology, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Tuesday's after hours session: top gainers and losers
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Merger with Inmagene Biopharmaceuticals
From Ikena Oncology, Inc.
Via GlobeNewswire
The Analyst Landscape: 4 Takes On Ikena Oncology
Via Benzinga
Traws Pharma Announces Management Updates
From Traws Pharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology: Q4 Earnings Insights
Via Benzinga
Ikena Oncology Reports Third Quarter 2024 Financial Results
Strong financial position with $138 million in cash and investments at close of third quarter 
From Ikena Oncology, Inc.
Via GlobeNewswire
IKNA Stock Earnings: Ikena Oncology Beats EPS for Q2 2024
IKNA stock results show that Ikena Oncology beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Ikena Oncology Reports Second Quarter 2024 Financial Results
Strong financial position with $145 million in cash and investments at close of second quarter 
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Discontinues IK-930 Program And Cuts Workforce, Analyst Calls It 'Disappointing'
Ikena Oncology halts its IK-930 program after reviewing clinical data and resources, focusing on the novel MEK-RAF molecular glue, IK-595. 
Via Benzinga
Why Bank of Montreal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
This American Airlines Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to start the day with a breakdown of the biggest pre-market stock movers traders are going to want to watch on Wednesday morning! 
Via InvestorPlace
UPDATE – Ikena Oncology Announces Strategic Update
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Announces Strategic Update
From Ikena Oncology, Inc.
Via GlobeNewswire
IKNA Stock Earnings: Ikena Oncology Beats EPS for Q1 2024
IKNA stock results show that Ikena Oncology beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer
From Ikena Oncology, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Ikena Oncology Refocuses on Key Programs: Analysts Maintain Outperform Ratings Amid Strategic Organizational Changes
Ikena Oncology optimizes resources for targeted oncology programs IK-930 & IK-595. Clinical updates expected H2 2024. Workforce reduced by 35%. Financially secure with $175M cash. Strategic focus on... 
Via Benzinga
Ikena Oncology Outlines Key Priorities and Provides Corporate Updates
From Ikena Oncology, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.